Year 6 data from the ULTIMATE I & II open-label extensions showed an annualized relapse rate of 0.012 on continuous ublituximab (BRIUMVI), roughly one relapse per 83 patient-years. Over six years, 10.1% of continuously treated patients had 24-week confirmed disability progression versus 15.9% in those who switched from teriflunomide (HR 0.658; p=0.0238), while 17% achieved 24-week confirmed disability improvement versus 13.3% in switchers (HR 1.414; p=0.0396). Safety remained consistent with earlier phases, immunoglobulins stayed above the lower limit of normal on average, and no new safety signals emerged. In ENABLE, a Phase 4 observational cohort, on-treatment ARR was 0.015 with 99.5% of participants relapse-free. Separately, ENHANCE data indicated a consolidated 600 mg Day 1 infusion was well tolerated across 1–4-hour durations, with lowest infusion reactions at four hours; a randomized, label-enabling comparison to standard loading is underway.
The core development: TG Therapeutics is using long-horizon efficacy and safety, plus dosing simplification, to tighten BRIUMVI’s positioning in the crowded anti-CD20 RMS class. The ECTRIMS package pairs durability from controlled trials with real-world consistency and advances a potentially simpler initiation regimen that could remove the two-visit loading step. The decreasing ARR across years three to six (0.053 → 0.032 → 0.020 → 0.012) reinforces a sustained suppression signal while the disability analyses support early initiation over delayed switch.
Strategically, this is a convenience-and-proof campaign aimed at eroding inertia around entrenched competitors. Ocrelizumab’s every-six-month IV cadence and ofatumumab’s monthly self-injection define the category’s operational trade-offs; BRIUMVI competes on infusion time and now seeks to collapse the loading schedule to further reduce friction at treatment start. The inclusion of a label-enabling randomized component for dosing is the critical regulatory lever. Real-world outcomes that track with the pivotal program, alongside stable immunoglobulins at the cohort level, are designed to ease payer and guideline hesitancy around class-wide concerns about infections and hypogammaglobulinemia during multi-year exposure.
For sites and health systems, a single 600 mg Day 1 infusion could consolidate chair time and staffing around initiation, decreasing appointment load and simplifying patient logistics, albeit with a longer first visit if four hours becomes the preferred default to minimize infusion reactions. That calculus will matter for infusion suite throughput and scheduling models, particularly as MS programs compete with oncology for IV capacity. For sponsors and CROs, the disability outcomes versus delayed switch will encourage protocol designs that emphasize earlier CD20 deployment and may influence control-arm selection and crossover allowances. Regulators will focus on the robustness of the label-enabling trial and the external validity of ENABLE’s diverse cohort as they weigh dosing changes and real-world extrapolation. Payers will scrutinize whether fewer visits and lower relapse rates translate into measurable utilization offsets relative to comparator anti-CD20s.
Next, the field will watch the randomized ENHANCE readout and the resultant regulatory path for loading consolidation, including whether one- to two-hour infusions can be justified without a tolerability penalty. Longer-term, continued surveillance of serious infections and immunoglobulin trends beyond six years will be important as lifetime exposure becomes the norm in RMS. Commercially, the question is whether operational simplicity at initiation can meaningfully shift share against incumbents without head-to-head data. If TG can secure a dosing update and maintain the real-world safety signal, BRIUMVI becomes a more straightforward add for infusion centers—and a more credible challenger in payer negotiations—though the class’s safety optics and capacity constraints will remain the gating factors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
